RESUMO
The present study aimed to investigate the effect of microRNA155 (miR155) on palmitateinduced vascular endothelial cell injury in human umbilical vein endothelial cells (HUVECs) via the regulation of the Wnt signaling pathway. HUVECs were treated with 0.1 mM palmitate. After transfection with mimic, antagomir or the Wnt pathway inhibitor XAV939, HUVECs were divided into six treatment groups: Control, palmitate, mimic + palmitate, mimic + palmitate + XAV939, antagomir + palmitate, antagomir + palmitate + XAV939. miR155 expression was detected using reverse transcriptionquantitative PCR. The expression levels of the Wnt signaling pathwayrelated factors ßcatenin and Cyclin D, and the inflammatory factors interleukin6 (IL6) and tumor necrosis factorα (TNFα), were detected using western blot analysis. MTT and Transwell assays were used to detect the proliferation and migration of cells, respectively. Apoptosis and reactive oxygen species (ROS) levels were determined using flow cytometry. The localization of ßcatenin in cells was determined by immunofluorescence. Palmitate reduced the expression level of miR155 in HUVECs. In palmitateinduced HUVECs, overexpression of miR155 promoted cell proliferation, reduced the levels of apoptosis, downregulated IL6 and TNFα expression, and reduced ROS levels. Inhibition of the Wnt signaling pathway enhanced the antiendothelial cell injury effect caused by the overexpression of miR155 in palmitateinduced HUVECs, thereby promoting proliferation, reducing apoptosis, downregulating the levels of inflammatory factors and reducing ROS levels. In summary, overexpression of miR155 inhibited palmitateinduced apoptosis, ROS production and levels of inflammatory factors, and promoted the proliferation of HUVECs by negatively regulating the Wnt signaling pathway. This present study provides a theoretical basis for the prevention and treatment of cardiovascular diseases associated with endothelial cell injury.
Assuntos
Apoptose/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/metabolismo , MicroRNAs/biossíntese , Ácido Palmítico/farmacologia , Via de Sinalização Wnt/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/patologia , Humanos , Espécies Reativas de Oxigênio/metabolismoRESUMO
Superior mesenteric arteriovenous fistulae (SMAVFs) are extremely rare with no consensus about therapeutic indications and optimal approach. Here, we present a case of a symptomatic SMAVF found in a young patient a few years after a penetrating abdominal injury. Following a complex clinical management of the acute status, we successfully managed the fistula with 3 covered stents in 2 consecutive endovascular procedures. Technical details of the performed procedures, including the main pitfalls and chosen solutions, have been explored and discussed.